... SEATTLE May 20 /- Omeros Corporation today... Advancing another PharmacoSurgery(TM) product candidate into clinical...OMS201 is one of the four clinical development programs in theCompany...The Phase 1 randomized double-blind vehicle-controlled andparallel-...

SEATTLE, May 20 /PRNewswire-FirstCall/ -- Omeros Corporation today
announced that it has begun patient enrollment for the Phase 1 study of
OMS201, the Company's second PharmacoSurgery(TM) drug product candidate,
for use during urological surgery. At least 24 patients undergoing
unilateral ureteroscopic removal of stones with a maximum diameter of 12 mm
located in the renal-collecting system or ureter will be enrolled in the
study.

"Advancing another PharmacoSurgery(TM) product candidate into clinical
development marks an important milestone for Omeros," said Dr. Gregory A.
Demopulos, Chairman and Chief Executive Officer of Omeros. "From our
PharmacoSurgery(TM) platform, Omeros is developing a series of product
candidates to improve clinical outcomes for surgical patients. The study
for OMS201 expands our PharmacoSurgery(TM) platform into urological
surgery."

OMS201 is one of the four clinical development programs in the
Company's PharmacoSurgery(TM) platform. PharmacoSurgery(TM) product
candidates are combinations of therapeutic agents designed to act
simultaneously at multiple discrete targets to preemptively block the
molecular-signaling and biochemical cascade caused by surgical trauma and
to provide clinical benefits both during and after surgery. The lead
product candidate in the PharmacoSurgery(TM) platform is OMS103HP, which is
currently in two Phase 3 clinical programs evaluating OMS103HP's safety and
ability to improve postoperative joint function and reduce pain following
arthroscopic surgery.

The Phase 1 randomized, double-blind, vehicle-controlled and
parallel-assigned study of OMS201 is designed to evaluate the systemic
absorption and safety of OMS201 in patients receiving primary treatment by
endoscopic removal of urinary stones. OMS201, developed from Omeros'
proprietary PharmacoSurgery(TM) platform, is designed for use during
urological surgery, including uroendoscopic procedures such as
ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added
to standard irrigation solutions in urological surgery, OMS201 is delivered
during the operation directly to the surgical site to inhibit surgically
induced inflammation, pain and smooth muscle spasm.

Principal Investigators are Ralph Clayman, MD, Chair of the Department
of Urology at University of California Irvine, and Margaret Pearle, MD,
PhD, Professor of Urology at University of Texas Southwestern.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company
committed to discovering, developing and commercializing products focused
on inflammation and disorders of the central nervous system. Omeros' most
clinically advanced product candidates are derived from its proprietary
PharmacoSurgery(TM) platform designed to improve clinical outcomes of
patients undergoing arthroscopic, ophthalmological, urological and other
surgical and medical procedures. Omeros has four ongoing
PharmacoSurgery(TM) clinical development programs, and its lead product
candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use
during arthroscopic surgery to improve postoperative joint function and
reduce postoperative pain. Omeros is also building a diverse pipeline of
preclinical programs targeting inflammation and central nervous system
disorders.

(Date:12/8/2016)... -- A Small Business Innovative Research (SBIR) grant has ... to Phoenix -based NeuroEM Therapeutics, Inc. ... will seek to determine an optimal set of treatment ... to treat Alzheimer,s Disease. The grant will also investigate ... other neurologic disorders such as Parkinson,s Disease and PTSD. ...

(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have contributed ... to CompScope™ Medical Benchmarks for California, 17th Edition , a study by the ... per claim in California decreased 4 percent in 2013 and then 3 percent in ...

(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Little Rock, has initiated a charity drive to ... the National Foundation to End Senior Hunger, Arkansas ranks first in senior hunger ...

(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and ... and around the Cape Coral area, is embarking on a charity drive with the ... Florida. , The Harry Chapin Food Bank of Southwest Florida works to provide fresh ...

(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again ... that it is one of the early adopters completing EU-U.S. Privacy Shield Certification from ... to provide companies on both sides of the Atlantic with a mechanism to comply ...

(Date:12/7/2016)... ... December 07, 2016 , ... Children ... bodies, a researcher at the Icahn School of Medicine at Mount Sinai has ... found that when young children are exposed to secondhand marijuana smoke, measurable amounts ...